Literature DB >> 16005096

Serum carotenoid concentrations are inversely associated with serum aminotransferases in hyperglycemic subjects.

Minoru Sugiura1, Mieko Nakamura, Yoshinori Ikoma, Masamichi Yano, Kazunori Ogawa, Hikaru Matsumoto, Masaya Kato, Makoto Ohshima, Akihiko Nagao.   

Abstract

Hyperglycemia increases the generation of free radicals by glucose auto-oxidation, and the increment of free radicals may lead to liver cell damage. In this study, we tested the hypothesis that hyperglycemia-induced increases of serum liver enzymes among its physiological concentration would be inversely associated with serum antioxidant carotenoid level. Study subjects were 857 male and female Japanese who had received health examinations in 2003. Those with a history of liver disease and excessive alcohol drinkers were excluded. The associations of serum six-carotenoid concentrations with serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) stratified by glucose tolerance status were evaluated cross-sectionally. Serum AST and ALT concentrations in the groups of impaired fasting glucose (IFG) and diabetes were significantly higher than those in the normal group. The multivariate-adjusted means of the serum AST and ALT concentrations in IFG and diabetes group were significantly low in accordance with the tertiles of the serum beta-cryptoxanthin and beta-carotene concentrations. The most inverse association of serum liver enzyme and carotenoid concentration was observed in beta-cryptoxanthin. Antioxidant carotenoid, especially beta-cryptoxanthin, may act a deterrent substance against increasing the serum aminotransferase in the earlier pathogenesis of liver dysfunction among hyperglycemic subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005096     DOI: 10.1016/j.diabres.2005.05.004

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  8 in total

Review 1.  Functional foods and their role in cancer prevention and health promotion: a comprehensive review.

Authors:  Mohammad Aghajanpour; Mohamad Reza Nazer; Zia Obeidavi; Mohsen Akbari; Parya Ezati; Nasroallah Moradi Kor
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

2.  Prevention of Adiposity by the Oral Administration of β-Cryptoxanthin.

Authors:  Katsuhiko Takayanagi
Journal:  Front Neurol       Date:  2011-11-23       Impact factor: 4.003

Review 3.  Cancer chemoprevention by carotenoids.

Authors:  Takuji Tanaka; Masahito Shnimizu; Hisataka Moriwaki
Journal:  Molecules       Date:  2012-03-14       Impact factor: 4.411

4.  Effect of a high-protein diet with β-cryptoxanthin supplementation on metabolic risk factors, oxidative and inflammatory biomarkers in non-alcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled clinical trial.

Authors:  Fatemeh Haidari; Abdollah Hojhabrimanesh; Bizhan Helli; Seyed Saeid Seyedian; Kambiz Ahmadi-Angali
Journal:  Trials       Date:  2018-11-16       Impact factor: 2.279

5.  Serum Lutein and Zeaxanthin Are Inversely Associated with High-Sensitivity C-Reactive Protein in Non-Smokers: The Mikkabi Study.

Authors:  Mieko Nakamura; Minoru Sugiura
Journal:  Antioxidants (Basel)       Date:  2022-01-28

6.  A Higher Serum Anion Gap Is Associated with the Risk of Progressing to Impaired Fasting Glucose and Diabetes.

Authors:  Yingchao Zhang; Fengran Xiong; Ruxuan Zhao; Tingting Shi; Jing Lu; Jinkui Yang
Journal:  Int J Endocrinol       Date:  2021-12-13       Impact factor: 3.257

7.  Greater serum carotenoid levels associated with lower prevalence of nonalcoholic fatty liver disease in Chinese adults.

Authors:  Yi Cao; Cheng Wang; Jun Liu; Zhao-min Liu; Wen-hua Ling; Yu-ming Chen
Journal:  Sci Rep       Date:  2015-08-10       Impact factor: 4.379

Review 8.  Watermelon lycopene and allied health claims.

Authors:  Ambreen Naz; Masood Sadiq Butt; Muhammad Tauseef Sultan; Mir Muhammad Nasir Qayyum; Rai Shahid Niaz
Journal:  EXCLI J       Date:  2014-06-03       Impact factor: 4.068

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.